CHA Biotech Co., Ltd.

As of March 31, 2026, CHA Biotech Co., Ltd. carries a market capitalization of 1.61T, placing it among publicly traded companies globally. Its enterprise value stands at 2.63T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, CHA Biotech Co., Ltd. has 92.97M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 1.03, and the price-to-book ratio stands at 3.13.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.63T versus a market cap of 1.61T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, CHA Biotech Co., Ltd. maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.60, indicating elevated leverage, while an interest coverage ratio of -0.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, CHA Biotech Co., Ltd. posted a negative return on equity (ROE) of -18.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.95, reflecting losses generated across the asset base. The company generates approximately 3.76B in revenue per employee across its workforce of 344.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 17.55 indicates how many times CHA Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, CHA Biotech Co., Ltd. recorded 3.13B in income tax expense. The company reported a pretax loss of -119.22B and -73.45B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, CHA Biotech Co., Ltd.'s stock has declined approximately 35.50% over the past 52 weeks. The 50-day moving average sits at 8,215.20, while the 200-day moving average is 13,538.80.

Over the twelve months ended March 31, 2026, CHA Biotech Co., Ltd. generated 1.29T in revenue and converted that into -73.45B in net income, yielding earnings per share of -1,473.49. EBITDA reached -9.86B, while operating income came in at -66.42B.

As of March 31, 2026, CHA Biotech Co., Ltd. holds 435.81B in cash and equivalents against 952.32B in total debt, resulting in a net debt position of 516.19B. Total book value stands at 514.86B, with working capital of -140.75B providing operational flexibility.

CHA Biotech Co., Ltd. produced -103.34B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -188.04B in capital expenditures, free cash flow totaled -291.38B - equivalent to -3,789.51 per share.

Over the twelve months ended March 31, 2026, CHA Biotech Co., Ltd. posted a gross margin of 28.39, reflecting its pricing power and cost economics. The operating margin of -5.13 and net profit margin of -5.68 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -20.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.28, meaning CHA Biotech Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CHA Biotech Co., Ltd.'s most recent stock split took place on April 9, 2025 with a 12:13 split ratio.

As of March 31, 2026, CHA Biotech Co., Ltd. has an Altman Z-Score of 1.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.